Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
894.51
+31.65 (+3.67%)
Streaming Delayed Price
Updated: 3:24 PM EST, Nov 3, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Eli Lilly (LLY) Stock Trades Up, Here Is Why
October 30, 2025
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the morning session after the company reported a "beat and raise" quarter.
Via
StockStory
Topics
Artificial Intelligence
Economy
Government
10 Health Care Stocks Whale Activity In Today's Session
October 30, 2025
Via
Benzinga
Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera
October 30, 2025
Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.
Via
Investor's Business Daily
Topics
Economy
Government
Nvidia's $5 Trillion Milestone Turns These AI ETFs Into Hot Trades
October 30, 2025
Nvidia's $5 trillion valuation record is igniting momentum across semiconductor and AI-themed ETFs as investors chase the next leg of the chip supercycle.
Via
Benzinga
Topics
Artificial Intelligence
ETFs
Earnings Scheduled For October 30, 2025
October 30, 2025
Via
Benzinga
Earnings Outlook For Eli Lilly
October 29, 2025
Via
Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
October 30, 2025
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...
Via
Benzinga
Topics
Economy
Tech Titans Tumble, Alphabet Soars as Market Opens Mixed on AI Spending Jitters
October 30, 2025
The U.S. stock market opened with a palpable sense of divergence on October 30, 2025, as investors grappled with a mixed bag of quarterly earnings and forward-looking statements from the nation's...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Fraud
Eli Lilly (LLY) Q3 2025 Earnings Call Transcript
October 30, 2025
Eli Lilly (LLY) Q3 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
Eli Lilly CEO Dave Ricks Reportedly Says Company Eyeing Pain Relief Market With Weight Loss Drug Retatrutide
October 30, 2025
CEO Dave Ricks told CNBC that the first study the company plans to read out for Retatrutide will be on knee pain.
Via
Stocktwits
Navigating the Currents: Dow Jones Shows Resilience Amidst Fed's Caution and Geopolitical Shifts
October 30, 2025
The Dow Jones Industrial Average (DJIA) finds itself navigating a complex economic landscape as of October 30, 2025, exhibiting resilience despite a barrage of mixed signals from central bank policies,...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast
October 30, 2025
Eli Lilly reported Q3 revenue of $17.6 billion, beating estimates and raising 2025 guidance as Mounjaro and Zepbound sales surged.
Via
Benzinga
Unpacking the Latest Options Trading Trends in Eli Lilly
October 30, 2025
Via
Benzinga
Eli Lilly Delivers Strong Q3 Performance, Raises Earnings Outlook
October 30, 2025
Eli Lilly’s Q3 2025 revenue jumped 54% to $17.6 billion with adjusted EPS of $7.02, prompting the company to lift its full-year guidance.
Via
Talk Markets
These S&P500 stocks are moving in today's pre-market session
October 30, 2025
Get insights into the top gainers and losers in the S&P500 index of Thursday's pre-market session.
Via
Chartmill
Eli Lilly & Co (NYSE:LLY) Q3 2025 Earnings Beat Estimates, Fueling Pre-Market Rally
October 30, 2025
Eli Lilly's Q3 2025 results crushed estimates, driven by high demand for Mounjaro and Zepbound. The company raised its full-year outlook, sparking a stock rally.
Via
Chartmill
Topics
Earnings
Eli Lilly Blows Past Expectations On The Back Of Mounjaro, Zepbound
October 30, 2025
Shares jumped early Thursday after the drugmaker easily topped third-quarter forecasts.
Via
Investor's Business Daily
Eli Lilly (NYSE:LLY) Delivers Strong Q3 Numbers, Stock Soars
October 30, 2025
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 53.9% year on year to $17.6 billion. The company’s full-year revenue...
Via
StockStory
Understanding Market Records: Is This Sustainable Growth?
October 29, 2025
The global stock market is currently navigating an unprecedented era of record-breaking growth in late October 2025, a phenomenon largely orchestrated by the remarkable performance and pervasive...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Fraud
Nvidia Shatters Records: AI Powerhouse Hits $5 Trillion Market Cap, Reshaping Global Economy
October 29, 2025
In a historic moment for the technology and financial worlds, Nvidia Corporation (NASDAQ: NVDA) officially achieved an unprecedented $5 trillion market capitalization on Wednesday, October 29, 2025....
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Emissions
Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart
October 29, 2025
Eli Lilly partners with NVIDIA to build a powerful AI supercomputer and teams up with Walmart to expand affordable Zepbound access nationwide.
Via
Benzinga
Topics
Artificial Intelligence
Nvidia Shatters Records with $5 Trillion Market Cap, Cementing AI Revolution Leadership
October 29, 2025
Santa Clara, CA – October 29, 2025 – In a historic moment for the technology sector, Nvidia (NASDAQ: NVDA) has officially achieved an unprecedented $5 trillion market capitalization, becoming the first...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Nvidia's 2 Surprises; NVDA Soars On Trump-Fueled Hopes of China Blackwell Sales; Fed In Focus
October 29, 2025
Two Nvidia Shockers Please click here for an enlarged chart of NVIDIA Corp (NASDAQ:NVDA).
Via
Benzinga
Topics
Economy
Nvidia's AI Reign: Fueling Market Gains and Forging a New Industrial Revolution
October 29, 2025
Nvidia (NASDAQ: NVDA) stands as the undisputed titan of the artificial intelligence (AI) era, its stock performance a primary catalyst for the recent, unprecedented surge in global financial markets....
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
Via
Investor Brand Network
Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability
October 29, 2025
EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NYSE:LLY),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug
October 29, 2025
Zepbound vials will be offered for pick-up at Walmart pharmacies nationwide by mid-November.
Via
Stocktwits
1 Incredible Reason to Buy Novo Nordisk Stock (NVO) in November -- or Sooner
October 29, 2025
It offers compelling weight-loss drugs -- and a compelling stock price, too.
Via
The Motley Fool
Could This Anti-Obesity Drug Biotech Be Poised to Soar in 2026?
October 29, 2025
This stock has caught fire after some recent events, but how long will that last?
Via
The Motley Fool
Eli Lilly (LLY) To Report Earnings Tomorrow: Here Is What To Expect
October 28, 2025
Global pharmaceutical company Eli Lilly (NYSE:LLY) will be announcing earnings results this Thursday before market open. Here’s what investors should know.
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.